News

Dr Hemberger is currently a director of Zymogenetics, Chroma, Atani and Zosano Pharma. Previously, she was a director at Marion Merrell Dow, NeXstar Pharmaceuticals, Pharmion, Perrigo, Myogen and

As chief scientific officer, Dr Barnes will be responsible for all scientific affairs including R&D, product development, process engineering and clinical and regulatory affairs. Dr Barnes will also

Unlike other methods of fracture treatment, the IlluminOss photodynamic bone stabilization system is designed to enable the patient to have immediate joint mobility post procedure without the need

According to OrSense, the NBM-200MP system offers for the first time a non-invasive, continuous and accurate measurement of oxygen saturation under all physiological conditions, as well as a

Net loss for the year ended December 31, 2008 was $59.22 million or $2.01 per share, compared to $52.37 million or $2.10 per share for the prior year

According to CNS Response, the new patent presents novel use of the company’s protected methodology for development of new indications of FDA approved pharmaceuticals when using an EEG

According to Metabasis, MB07803 treatment resulted in dose-related, clinically meaningful and statistically significant reductions in day long glycemia (24-hour weighted mean glucose levels) at all doses evaluated (50mg,

Based in Birkerod, Denmark, Mr Moraviec will have global responsibility for the continence and critical care business unit, a new business unit formed following ConvaTec’s integration of Unomedical,

RXi Pharmaceuticals, a discovery-stage biopharmaceutical company, has reported a net loss of $4m, or $0.29 per share, for the fourth quarter of 2008, compared to a net loss